Skip to main content

Table 4 Summary of studies assessing the efficacy of bupivacaine-loaded lipid nanoparticle

From: New Updates Pertaining to Drug Delivery of Local Anesthetics in Particular Bupivacaine Using Lipid Nanoparticles

Author Study design Surgery Intervention/Placebo Primary end point Results
Gorfine et al. [54] Random controlled trial Hemorrhoidectomy DepoFoam Bupivacaine 300 mg compared with 0.9 % sodium chloride Numerical rating score (NRS), AUC 0–72 h Pain intensity scores were significantly decreased in the extended release bupivacaine group versus placebo (141.8 vs. 202.5, P < 0.001).
Smoot et al. [55] Random controlled trial Mammoplasty DepoFoam bupivacaine 600 mg compared with bupivacaine HCL 200 mg þ epinephrine 1:200,0000 NRS-Activity, AUC 0–72 h No statistical difference between the groups (AUC NRS-A, 441 vs. 468, P 1⁄4 0.3999).
Golf et al. [29] Random controlled trial Bunionectomy DepoFoam 120 mg compared to 0.9 % sodium chloride NRS AUC 0–24 h Pain intensity score was significantly decreased in lipid nanoparticle bupivacaine versus control, 123.9 in DepoFoam versus 146 in placebo, P < 0.0005.
Bramlett et al. [28] Random controlled trial Total knee arthroplasty DepoFoam bupivacaine (133, 266, 399, and 532 mg) compared to bupivacaine HCl 150 mg with epinephrine 1:200,000 NRS-A, AUC 0–96 h No statically significant difference between all DepoFoam groups versus bupivacaine HCl (P > 0.05).
Cohen et al. [56] Cohort study Colectomy DepoFoam 366 mg compared with postoperative PCA Total milligrams of opioids consumed after surgery and total cost of hospitalization Mean total amount of postsurgical opioids significantly less in DepoFoam compared to PCA group (57 vs. 115 mg, P 1⁄4 0.025). Average cost of hospitalization significantly less in DepoFoam versus PCA (US$ 8766 vs. US$ 11,850 P 1⁄4 0.027).